A research exhibited the contemporary approved approaches for the workup required to diagnose patients with early-stage non-small cell lung cancer (NSCLC) and their following treatment procedure. The researchers review the basis of these suggestions. At a preliminary presentation of the patients, roughly 30% of them have been found to have early-stage disease. Especially in asymptomatic patients with newly diagnosed lung cancer, the extent to which a search for the metastatic disease should be conducted is not yet known by the surgeons. In most cases, physicians concur that a vital component of treating stage I and II non-small cell lung cancer (NSCLC) is surgery. Further research is required to understand what adjuvant therapies can do in early-stage diseases. The growth of locoregional disease (stage IIIa) non-small cell lung cancer (NSCLC) as a disease is evident. And, it is probable that multimodality therapy may be a part of the treatment for this disease. But, the treatment’s timing and sequence are part of profound research. Researchers made suggestions whenever possible in the study. They were based on the results gathered from randomized clinical trials.